pour la recherche uniquement
Réf. CatalogueS5742
| Lignées cellulaires | Type dessai | Concentration | Temps dincubation | Formulation | Description de lactivité | PMID |
|---|---|---|---|---|---|---|
| SK-N-MC | Antiproliferative assay | 72 hrs | Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 4.51 μM. | 17602603 | ||
| SK-N-MC | Antiproliferative assay | 72 hrs | Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 5 μM. | 19601577 | ||
| SK-N-MC | Antiproliferative assay | 72 hrs | Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 7.35 μM. | 19216562 | ||
| A549 | Antiproliferative assay | 72 hrs | Antiproliferative activity at human A549 cells after 72 hrs by MTT assay, IC50 = 7.5 μM. | 22861499 | ||
| SK-N-MC | Antiproliferative assay | 96 hrs | Antiproliferative activity against human SK-N-MC cells after 96 hrs by MTT assay, IC50 = 8.58 μM. | 17064069 | ||
| MDCK | Toxicity assay | Toxicity in MDCK cells by MTT method, IC50 = 9.49 μM. | 20041672 | |||
| SK-N-MC | Cytotoxicity assay | 72 hrs | Cytotoxicity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 9.89 μM. | 20303768 | ||
| SK-N-MC | Antiproliferative assay | 72 hrs | Antiproliferative activity at human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 10 μM. | 22861499 | ||
| DMS53 | Antiproliferative assay | 72 hrs | Antiproliferative activity at human DMS53 cells after 72 hrs by MTT assay, IC50 = 10 μM. | 22861499 | ||
| SK-MN-C | Antiproliferative assay | Antiproliferative activity against human SK-MN-C cells by MTT assay, IC50 = 12.05 μM. | 18159922 | |||
| SK-N-MC | Antiproliferative assay | 72 hrs | Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 12.5 μM. | 22858101 | ||
| SK-N-MC | Antiproliferative assay | Antiproliferative activity against human SK-N-MC cells by MTT assay, IC50 = 14.22 μM. | 17963372 | |||
| SK-N-MC | Toxicity assay | Toxicity in human SK-N-MC cells by MTT method, IC50 = 16.04 μM. | 20041672 | |||
| SK-N-MC | Antiproliferative assay | 72 hrs | Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 16.81 μM. | 28841514 | ||
| SK-N-MC | Antiproliferative assay | 72 hrs | Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 17.07 μM. | 21055950 | ||
| SK-N-MC | Antiproliferative assay | 72 hrs | Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay, IC50 = 17.07 μM. | 22172311 | ||
| U2OS | Function assay | 30 mins | Activation of human HIF1alpha expressed in DFX-induced human U2OS cells incubated for 30 mins prior to DFX-induction measured after overnight incubation by luciferase reporter gene assay, EC50 = 17.8 μM. | 22172704 | ||
| HL60 | Cytotoxicity assay | Cytotoxicity against human HL60 cells by alamar blue assay, GI50 = 18.4 μM. | 23266185 | |||
| SK-N-MC | Antiproliferative assay | 72 hrs | Antiproliferative activity against human SK-N-MC cells measured after 72 hrs at 37 degC by MTT assay, IC50 = 21.63 μM. | 23312948 | ||
| SK-N-MC | Antiproliferative assay | Antiproliferative activity against human SK-N-MC cells, IC50 = 22 μM. | 19601577 | |||
| SK-N-MC | Antiproliferative assay | 72 hrs | Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTS assay, IC50 = 22.7 μM. | 21846118 | ||
| SK-N-MC | Cytotoxicity assay | 72 hrs | Cytotoxicity against human SK-N-MC cells assessed as growth inhibition after 72 hrs by MTT assay, IC50 = 22.7 μM. | 23276209 | ||
| K562 | Cytotoxicity assay | Cytotoxicity against human K562 cells, GI50 = 33.1 μM. | 23266185 | |||
| HT29 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human HT29 cells after 72 hrs by MTS assay, IC50 = 36.1 μM. | 18345610 | ||
| HT-29 | Cell cycle assay | 10 uM | 24 hrs | Cell cycle arrest in nocodazole pretreated human HT-29 cells assessed as accumulation at M phase at 10 uM after 24 hrs | 20353152 | |
| HT-29 | Cell cycle assay | 5 uM | 24 hrs | Cell cycle arrest in nocodazole pretreated human HT-29 cells assessed as accumulation at M phase at 5 uM after 24 hrs | 20353152 | |
| HCT116 | Function assay | 24 hrs | Photocytotoxicity against human HCT116 cells expressing wild type p53 incubated for 24 hrs followed by light irradiation measured after 24 hrs by MTS assay in presence of ALA and FeCl3 | 24900837 | ||
| HeLa | Bacteriostatic assay | >100 uM | 1 hr | Bacteriostatic activity against Chlamydia trachomatis serovar L2 infected in human HeLa cells assessed as growth inhibition compound treated at >100 uM for 1 hr prior infection measured 24 hrs post infection by microscopy | 25027937 | |
| SK-N-BE(2)-M17 | Cytoprotection assay | 1 mM | 2 hrs | Cytoprotection against PQ-induced cell death in human SK-N-BE(2)-M17 cells assessed as increase in cell viability at 1 mM pretreated for 2 hrs followed by 1 mM PQ addition measured after 24 hrs by LDH assay | 28285915 | |
| SK-N-BE(2)-M17 | Cytoprotection assay | 1 mM | 2 hrs | Cytoprotection against H2O2-induced cell death in human SK-N-BE(2)-M17 cells assessed as increase in cell viability at 1 mM pretreated for 2 hrs followed by 1 mM H2O2 addition measured after 24 hrs by LDH assay | 28285915 | |
| SK-N-BE(2)-M17 | Cytoprotection assay | 1 mM | 2 hrs | Cytoprotection against PQ-induced cell death in human SK-N-BE(2)-M17 cells assessed as increase in cell viability at 1 mM pretreated for 2 hrs followed by 1 mM PQ addition measured after 24 hrs by MTT assay | 28285915 | |
| SK-N-BE(2)-M17 | Cytoprotection assay | 1 mM | 2 hrs | Cytoprotection against H2O2-induced cell death in human SK-N-BE(2)-M17 cells assessed as increase in cell viability at 1 mM pretreated for 2 hrs followed by 1 mM H2O2 addition measured after 24 hrs by MTT assay | 28285915 | |
| DAOY | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 29435139 | |||
| BT-37 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 29435139 | |||
| SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 29435139 | |||
| BT-12 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 29435139 | |||
| OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 29435139 | |||
| Cliquez pour voir plus de données expérimentales sur la lignée cellulaire | ||||||
| Poids moléculaire | 656.79 | Formule | C26H52N6O11S |
Stockage (À compter de la date de réception) | 3 years -20°C powder |
|---|---|---|---|---|---|
| N° CAS | 138-14-7 | -- | Stockage des solutions mères |
|
|
|
In vitro |
DMSO
: 100 mg/mL
(152.25 mM)
Water : 100 mg/mL Ethanol : Insoluble |
|
In vivo |
|||||
Étape 1 : Saisir les informations ci-dessous (Recommandé : Un animal supplémentaire pour tenir compte des pertes pendant lexpérience)
Étape 2 : Saisir la formulation in vivo (Ceci est seulement le calculateur, pas la formulation. Veuillez nous contacter dabord sil ny a pas de formulation in vivo dans la section Solubilité.)
Résultats du calcul :
Concentration de travail : mg/ml;
Méthode de préparation du liquide maître DMSO : mg médicament prédissous dans μL DMSO ( Concentration du liquide maître mg/mL, Veuillez nous contacter dabord si la concentration dépasse la solubilité du DMSO du lot de médicament. )
Méthode de préparation de la formulation in vivo : Prendre μL DMSO liquide maître, puis ajouterμL PEG300, mélanger et clarifier, puis ajouterμL Tween 80, mélanger et clarifier, puis ajouter μL ddH2O, mélanger et clarifier.
Méthode de préparation de la formulation in vivo : Prendre μL DMSO liquide maître, puis ajouter μL Huile de maïs, mélanger et clarifier.
Note : 1. Veuillez vous assurer que le liquide est clair avant dajouter le solvant suivant.
2. Assurez-vous dajouter le(s) solvant(s) dans lordre. Vous devez vous assurer que la solution obtenue, lors de lajout précédent, est une solution claire avant de procéder à lajout du solvant suivant. Des méthodes physiques telles que le vortex, les ultrasons ou le bain-marie chaud peuvent être utilisées pour faciliter la dissolution.
| Targets/IC50/Ki |
HIF-1α
Beta Amyloid
Ferroptosis
|
|---|---|
| In vitro |
Le Deferoxamine mesylate, le chélateur de fer et inhibiteur de la ferroptosis, sauve la mort des neutrophiles induite par le sérum du lupus érythémateux systémique (LES), suggérant que la ferroptosis pourrait être la principale forme de mort des neutrophiles dans le LES. |
| In vivo |
Le Deferoxamine mesylate (Ba 33112, Desferrioxamine B, DFOM, NSC 644468) est le sel mésylate de Deferoxamine, qui forme des complexes de fer et est utilisé comme agent chélateur. |
Références |
|
Tel: +1-832-582-8158 Ext:3
Si vous avez dautres questions, veuillez laisser un message.